An interventional study of Cyclokapron in vonWillebrand Disease, Hemophilia and Platelet Coagulation Disorders, sponsored by Mary M. Gooley Hemophilia Center. Completed at 1 site in United States. Open to female participants aged 8 Years to 60 Years. Per ClinicalTrials.gov, last updated 2008-09-19.
Sponsored by Mary M. Gooley Hemophilia Center · Not applicable, Interventional, and Treatment
The high percentage of failure using available non-surgical options to treat menorrhagia in women with bleeding disorders shows a continuing need for innovative treatments. This has led to development of this protocol in order to make available tranexamic acid as a potentially effective menorrhagia therapy option in women with an underlying bleeding disorder. We anticipate that Tranexamic Acid may be a beneficial choice for controlling menorrhagia in bleeding disorder patients.
Women with heavy periods and with a diagnosed bleeding disorders are prescribed cyclokapron pills to be taken during their periods. Their periods are assessed at 3 and 6 months by filling out a pictorial blood assessment chart. If the drug appears to be working with no adverse effects the patients can continue to take the medication as long as it is available with follow up with the investigator every 6 months.
885 studies on the registry are indexed under Hemophilia A; 139 are open to participants now.
This study's enrollment of 13 is below the median of 27 across 523 interventional studies indexed under Hemophilia A.
Browse Hemophilia A studies →This is the only study on the registry with Mary M. Gooley Hemophilia Center as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
on treatment
Drug: Cyclokapron
(2) 500mg tablets taken by mouth every 6-8 hours
Also known as: tranexamic Acid
Reduced pictorial blood assessment chart scores from baseline
Time frame: 3 and 6 months after start of medication
increased hematocrit
Time frame: 3 and 6 months from start of medication
The record gives a start of Apr 2003, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid